ReviewCureus2026
Oncological Safety of Testosterone Replacement Therapy in Men With a History of Prostate Cancer: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review aims to map, critically evaluate, and integrate current evidence on the oncological safety of testosterone replacement therapy (TRT) in men with a history of prostate cancer. For decades, TRT was contraindicated in this population due to the "androgen hypothesis"; however, recent evidence and the "saturation model hypothesis" challenge this dogma. A comprehensive search of seven databases, with no restrictions on publication date, yielded 2,284 studies, of which nine met the inclusion criteria. The reviewed studies, primarily retrospective cohorts and case series, reported that TRT does not appear to increase the risk of biochemical recurrence, disease progression, or mortality in men with low- to intermediate-risk localized prostate cancer following radical prostatectomy, radiotherapy, or under active surveillance. Evidence for high-risk or advanced disease remains limited, and TRT continues to be contraindicated in recurrent or metastatic cases outside of clinical trials. These findings challenge historical restrictions and support the cautious use of TRT in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.